source
- Eli Lilly’s retatrutide meets primary goals in phase 3 obesity trials with ~22% weight loss but no clear heart benefitEli Lilly reported that its triple‑hormone agonist retatrutide achieved the primary endpoints in two phase 3 obesity studies, TRIUMPH‑2 and TRIUMPH‑3. The drug was tested at a 12 mg dose against pl…
- Lilly's obesity drug shows strong weight loss but fails to demonstrate cardiovascular benefit in heart disease trialEli Lilly released Phase 3 results for its next‑generation obesity therapy retatrutide, showing it produces substantial weight loss in a trial of nearly 2,000 participants with severe obesity and e…